Price
No data yet.
Social Signal Score
Revenue
$1.16B+216.73%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jan van de Winkel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3,119
- Beta
- 0.69
- Country
- DK
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 13.20
Financials
Revenue
$1.16B+216.7%Net Income
$303.00M+60.4%EBITDA
$431.00M+121.3%Free Cash Flow
$48.00M-76.4%EPS (diluted)
$0.49+58.1%Shares Outstanding (diluted)
617.11M-0.1%Operating Expenses
$664.00MCash & Debt
$1.50BReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.72B | $963.76M | $1.55 |
| 2024 | $21.53B | $7.84B | $12.14 |
| 2023 | $16.47B | $4.35B | $6.60 |
| 2022 | $14.51B | $5.45B | $8.34 |
| 2021 | $8.42B | $2.96B | $4.52 |
| 2020 | $10.11B | $4.76B | $7.30 |
| 2019 | $5.37B | $2.17B | $3.44 |
| 2018 | $3.03B | $1.47B | $2.40 |
| 2017 | $2.37B | $1.10B | $1.81 |
| 2016 | $1.82B | $1.19B | $1.98 |
| 2015 | $1.13B | $763.51M | $1.31 |
| 2014 | $850.38M | $301.30M | $0.54 |
| 2013 | $663.57M | $112.36M | $0.22 |
| 2012 | $484.64M | $-487.12M | $-1.06 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $2.28
- Implied price
- $45.57
- Return from $34.34
- 5.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $22.66 — -34.0% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 14 | 17 | 20 | 23 | 26 |
|---|---|---|---|---|---|
| -2.0% | -10.6% | -7.0% | -4.0% | -1.3% | 1.2% |
| 3.0% | -6.0% | -2.3% | 0.9% | 3.8% | 6.4% |
| 8.0% | -1.5% | 2.4% | 5.8% | 8.8% | 11.5% |
| 13.0% | 3.1% | 7.2% | 10.7% | 13.9% | 16.7% |
| 18.0% | 7.7% | 11.9% | 15.6% | 18.9% | 21.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsglobenewswire.com·5h ago·Neutral
Genmab to Participate in Upcoming Investor Conferences Media Release COPENHAGEN, Denmark; August 25, 2026 Genmab A/S (Nasdaq: GMAB ) announced today that members of its E xecutive Committee will participat e in fireside chats at the following investor conferences in September 2026 :
View source ↗
Earnings
Thu, Nov 5(in 2 months)
Consensus estimate $0.36 per share
Typical surprise +35.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.54 vs $0.37beat
- Thu, May 7$0.09 vs $0.15miss
- Tue, Feb 17$0.05 vs $0.46miss
- Thu, Nov 6$0.65 vs $0.48beat
- Thu, Aug 7$0.54 vs $0.39beat
- Thu, May 8$0.31 vs $0.23beat
Estimates and results for GMAB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.